Kangstem Biotech Co Ltd
217730
Company Profile
Business description
Kangstem Biotech Co Ltd develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.
Contact
512 Teheran-ro, Gangnam-gu
17th Floor, Sinan Building
Seoul
KORT: +82 28881590
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
Are investors too bearish on Australian equities?
A new report suggests the pessimism might be overdone.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.10 | 30.20 | 0.33% |
| CAC 40 | 8,200.88 | 15.70 | -0.19% |
| DAX 40 | 24,124.21 | 154.42 | -0.64% |
| Dow JONES (US) | 47,632.00 | 74.37 | -0.16% |
| FTSE 100 | 9,756.14 | 59.40 | 0.61% |
| HKSE | 26,346.14 | 87.56 | -0.33% |
| NASDAQ | 23,958.47 | 130.98 | 0.55% |
| Nikkei 225 | 51,222.78 | 84.87 | -0.17% |
| NZX 50 Index | 13,485.14 | 75.93 | 0.57% |
| S&P 500 | 6,890.59 | 0.30 | -0.00% |
| S&P/ASX 200 | 8,909.60 | 29.60 | 0.33% |
| SSE Composite Index | 4,016.29 | 0.05 | -0.00% |